ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

Impact and Risks of Chronic Anemia in Thalassemia Patients

Farrukh Shah

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

How I Treat Anemia in Myelofibrosis

Cleveland Clinic Taussig Cancer Institute

A. Jain

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ASH 2024 Review: Updates on the Management of MDS

Cleveland Clinic Taussig Cancer Institute

H. Carraway

Debate: There Is a Role for Anti-Inflammatory Treatment in MDS

MDS Foundation

L. Weeks

Cellular Therapies for Myeloid Malignancies

Moffitt Cancer Center

D. Sallman

ASH 2024 Insights: Ven + HMA vs. HMA Alone in TP53m HR-MDS - Real-Wo…

2024 ASH Annual Meeting Insights Hub

T. Badar

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

Year in Review 2024 - Highlights in MPNs and Impact on Practice

Oncology 2024 Year in Review

P. Bose

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin

ASH 2024 Summary: Overview of Non-Surgical Management of Heavy Menst…

2024 ASH Annual Meeting Insights Hub

A. Wheeler

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray